(1) Publication number:

0 378 254 A3

### (12)

#### EUROPEAN PATENT APPLICATION

(21) Application number: 90200004.1

(51) Int. Cl.5: C07D 401/14, C07D 471/04, C07D 405/14, A61K 31/505

② Date of filing: 03.01.90

(30) Priority: 09.01.89 GB 8900380

(43) Date of publication of application: 18.07.90 Bulletin 90/29

(a) Designated Contracting States: AT BE CH DE DK ES FR GB GR IT LI LU NL SE

B) Date of deferred publication of the search report: 09.01.91 Bulletin 91/02

7) Applicant: JANSSEN PHARMACEUTICA N.V. Turnhoutseweg 30 B-2340 Beerse(BE)

72 Inventor: Janssens, Frans E. Tinstraat 79 B-2830 Bonheiden(BE) Inventor: Kennis, Ludo E.J.

Guido Gezellestraat 50 B-2300-Turnhout(BE)

Inventor: Sommen, François M. Langenberg 49

B-2323-Wortel(BE)

Inventor: Dierckx, Ann C.J.

Zandhoef 8

B-2460-Kasterlee(BE)

# 2-Aminopyrimidinone derivatives.

Novel 2-aminopyrimidinone derivatives of formula

$$R^{5} - N \longrightarrow N \longrightarrow R^{3} \longrightarrow R^{2} \longrightarrow N \longrightarrow A^{1} \longrightarrow A^{1} \longrightarrow A^{2} \longrightarrow A^{4} : A^{3}$$
 (I),

#### wherein

 $-A^1 = A^2 - A^3 = A^4$  is -CH = CH - CH = CH, -N = CH - CH = CH, -CH = N - CH = CH, -CH = CH, -CH = CH

 $CH = N_{-}, -N = CH_{-}N = CH_{-}, -CH = N_{-}CH = N_{-};$ 

B is NR8, CH2, O, S, SO or SO<sub>2</sub>; R8 is hydrogen,  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl,  $C_{1-6}$ alkylcarbonyl,  $C_{1-6}$ alkyloxvcarbonyl or Ar2-C1-6 alkyl;

 $R^1$  is hydrogen,  $C_{1-10}$  alkyl,  $C_{3-6}$  cycloalkyl,  $Ar^1$ , mono- and di( $Ar^1$ )- $C_{1-6}$  alkyl, or a radical -Alk-G- $R^7$ ;

R2. R3 are hydrogen or C1-6 alkyl;

 $R^4$  is hydrogen,  $C_1$  -salkyl optionally substituted with  $Ar^2$ , pyridinyl, furanyl, 5-methyl-2-furanyl or  $C_1$  -salkyloxy;

 $R^5$  is hydrogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkylaminocarbonyl or  $Ar^2$ -aminocarbonyl;

R6 is hydrogen or C1-6 alkyl; or R5 and R6 taken together may form a bivalent radical of formula -CH2-CH2-,  $-CH_2-CH_2-CH_2-$ , -CH=CH-, -CH=N-, -N=CH-,  $-N=CH-CH_2-$ ;

n is 0, 1 or 2; the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof;

#### EP 0 378 254 A3

pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.



# EUROPEAN SEARCH REPORT

&: member of the same patent family, corresponding

document

EP 90 20 0004

tegory	Citation of document with indication, where appropriate, of relevant passages		Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CI.5)
A,C	EP-A-0 151 826 (JANSSEN Pages 2-19; claims	)	1,7-10	C 07 D 401/14 C 07 D 405/14 C 07 D 471/04
Α	EP-A-0 144 101 (JANSSEN Pages 2-23; page 49, exam		1,7-10	A 61 K 31/505 C 07 D 487/04
),A	EP-A-0 282 133 (JANSSEN Pages 1-16,24-29; claims	)	1,7-10	
D,A	EP-A-0 295 742 (JANSSEN Pages 1-10; claims	)	1,7-10	
D,A	EP-A-0 297 661 (JANSSEN Pages 1-14,28,30; claims	)	1,7-10	
				TECHNICAL FIELDS SEARCHED (Int. CI.5)
				C 07 D 401/00 C 07 D 405/00 C 07 D 471/00 C 07 D 487/00 C 07 D 519/00
	The present search report has be	een drawn up for all claims		
	Place of search Date of completion  The Hague 13 November		rch	Examiner
			90 FRANCOIS J.C.L.	
	Place of search  The Hague  CATEGORY OF CITED DOCUL  particularly relevant if taken alone particularly relevant if combined with document of the same catagory	13 November 90		FRANCOIS J.C.L. ment, but published on, or after

A: technological background

O: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention